OVID Jul 2024 5.000 put
- GlobeNewswire
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
Takeda’s Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effects in multiple key secondary efficacy endpoints all with p-values ≤ 0.008Takeda’s Skyway study in Lennox-Gastaut syndrome missed its primary endpoint of reduction in major motor drop seizuresSoticlestat had a consistent and favorable safety and tolerability profile in both studiesTakeda will move forward to discuss the t
- Zacks
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 26.09% and 40.95%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal yearA Phase 1, double-blind, multiple-ascending dose trial evaluating OV888 (GV101) is complete; topline safety data are expected in H1 2024Ovid expects to initiate a Phase 2 clinical program studying OV888 (GV101) in cerebral cavernous malformations in H2 2024Cash, cash equivalents and marketable securities were $90.
